Abidi Saba, Kumar Anoop, Dwivedi Shridhar, Sharma Vinod, Talegaonkar Sushama, John Denny
School of Allied Health Sciences and Management, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
JBI Evid Synth. 2025 Sep 1;23(9):1824-1831. doi: 10.11124/JBIES-24-00390. Epub 2025 Sep 9.
This systematic review will assess the cost-effectiveness of clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Antiplatelet drugs, including clopidogrel, ticagrelor, prasugrel, and aspirin, are crucial in managing ACS, preventing ischemia, and, ultimately, death in PCI patients. Clopidogrel is the main treatment for those who have undergone PCI, used either alone or with aspirin. The incidence of ACS is rising globally, and is a major cause of premature death for millions. ACS management involves continuous medical therapy and costly procedures such as PCI, significantly straining health care resources.
Studies will be eligible for inclusion if they report on the cost-effectiveness of clopidogrel in patients with ACS compared with other antiplatelet drugs.
This systematic review will adhere to the JBI methodology for systematic reviews of economic evaluation evidence. A preliminary search was conducted of MEDLINE (PubMed) using MeSH terms. Two independent reviewers will screen records at the title/abstract level, followed by full-text screening. Two reviewers will then assess methodological quality and extract data as per JBI guidelines. The JBI Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the included studies. The cost-effectiveness measures will be incremental cost, incremental cost per quality-adjusted life year gained, or incremental cost per disability-adjusted life year averted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to appraise the certainty of economic evidence, such as using resources and expenditure, for incorporating the results into the decision-making process.
PROSPERO CRD42024504614.
本系统评价将评估氯吡格雷在接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者中的成本效益。
抗血小板药物，包括氯吡格雷、替格瑞洛、普拉格雷和阿司匹林，在管理ACS、预防缺血以及最终预防PCI患者死亡方面至关重要。氯吡格雷是接受PCI患者的主要治疗药物，可单独使用或与阿司匹林联合使用。全球范围内ACS的发病率正在上升，是数百万人过早死亡的主要原因。ACS的管理涉及持续的药物治疗和诸如PCI等昂贵的治疗程序，这给医疗资源带来了巨大压力。
如果研究报告了氯吡格雷在ACS患者中与其他抗血小板药物相比的成本效益，则该研究将符合纳入标准。
本系统评价将遵循JBI经济评价证据系统评价方法。使用医学主题词（MeSH）对MEDLINE（PubMed）进行了初步检索。两名独立的评审人员将在标题/摘要层面筛选记录，随后进行全文筛选。然后，两名评审人员将根据JBI指南评估方法学质量并提取数据。将使用JBI经济评价优势排名矩阵来总结和比较纳入的研究。成本效益指标将是增量成本、每获得一个质量调整生命年的增量成本或每避免一个伤残调整生命年的增量成本。推荐分级评估、制定与评价（GRADE）方法将用于评估经济证据的确定性，例如使用资源和支出情况，以便将结果纳入决策过程。
PROSPERO CRD42024504614。
